Shell stock price slides with oil — what to watch before Feb 5 earnings

Shell stock price slides with oil — what to watch before Feb 5 earnings

Shell’s U.S. shares fell 1.7% to $75.73 on Monday as oil prices slid over 4% following signs of easing U.S.-Iran tensions. Brent crude settled at $66.30 a barrel. Investors are focused on Shell’s fourth-quarter results and dividend announcement due Feb. 5. Analysts expect major European oil firms to cut shareholder returns, mainly by reducing buybacks.
Tesco share price slips as grocery inflation cools — 3 dates investors are watching

Tesco share price slips as grocery inflation cools — 3 dates investors are watching

Tesco shares dipped 0.1% to 430.9 pence in early London trading, following new data showing UK grocery inflation slowed to 4.0%, its lowest since April. Tesco’s market share rose to 28.7% as sales climbed 4.4% in the 12 weeks to Jan. 25. Investors await the Bank of England’s Feb. 5 rate decision and UK CPI data on Feb. 18. Tesco’s next earnings report is due April 16.
3 February 2026
BP stock edges up as activist investors press for proof on oil-and-gas pivot

BP stock edges up as activist investors press for proof on oil-and-gas pivot

BP shares edged up 0.3% to 463.5 pence Tuesday morning as investors awaited fourth-quarter results due Feb. 10. The Australasian Centre for Corporate Responsibility filed a shareholder resolution seeking more clarity on BP’s shift from low-carbon to oil and gas spending. BP repurchased 2.86 million shares Monday, with 15.72 billion shares outstanding as of Jan. 31. Brent crude slipped 0.5% to $65.96 a barrel.
3 February 2026
GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts

GSK share price nears a one-year high ahead of earnings after Wave drug handback and R&D cuts

GSK shares edged up 0.1% to 1,926.5 pence Tuesday, nearing a one-year high ahead of its earnings report due Wednesday. The company is cutting about 350 R&D jobs in the UK and U.S. and recently returned rights to the WVE-006 drug candidate to Wave Life Sciences. Investors await CEO Luke Miels’ first major update and signals on cost controls and R&D priorities.
British American Tobacco share price ticks up on fresh buyback notice as dividend, Feb 12 results near

British American Tobacco share price ticks up on fresh buyback notice as dividend, Feb 12 results near

British American Tobacco shares rose 0.6% to 4,459 pence in early London trading after the company bought back 108,725 shares on Feb. 2, to be cancelled. BAT will pay its next dividend on Feb. 4 and release preliminary 2025 results on Feb. 12. The latest buyback reduced the share count to 2,176,779,980. Previous session volume was about 5.4 million shares.
3 February 2026
Glencore stock rises on Citi adviser talk as Rio Tinto deadline nears — what to watch next

Glencore stock rises on Citi adviser talk as Rio Tinto deadline nears — what to watch next

Glencore shares rose 0.9% to 505.6 pence in early London trading after reports it is close to hiring Citi for possible Rio Tinto merger talks. Rio Tinto faces a UK takeover deadline to clarify its intentions by Feb. 5. Both companies declined to comment. Investors await news on a possible deadline extension and Glencore’s full-year results due Feb. 18.
Rio Tinto share price: Glencore taps Citi as Feb. 5 takeover clock ticks

Rio Tinto share price: Glencore taps Citi as Feb. 5 takeover clock ticks

Glencore is close to appointing Citigroup as lead adviser for merger talks with Rio Tinto, sources say, ahead of a Feb. 5 UK takeover deadline. Rio Tinto shares closed up 0.95% at 6,802 pence Monday amid market volatility. Initial talks in January included a possible all-share merger. Major shareholders FMR LLC and FIL Limited disclosed recent purchases of Rio Tinto shares.
1 80 81 82 83 84 1,634

Stock Market Today

AstraZeneca stock price: What could move AZN next week as earnings loom

AstraZeneca stock price: What could move AZN next week as earnings loom

7 February 2026
AstraZeneca shares rose Friday, closing at $193.03 in New York, up 3.1%, and 14,104p in London, up 0.9%. The company reports full-year and Q4 2025 results Tuesday, with investors focused on 2026 guidance. The FDA this week issued a complete response letter for a subcutaneous Saphnelo filing, while granting Priority Review to Datroway for breast cancer. AstraZeneca recently shifted its primary U.S. listing to the NYSE.
Go toTop